PLSG Invests $450,000 in Three Companies
PITTSBURGH, Aug. 21 /PRNewswire/ -- The Pittsburgh Life Sciences Greenhouse (PLSG), the private/public partnership putting the region's life sciences industry on a fast track for growth, announced that the PLSG has invested a total of $450,000 in three companies: Applied Computational Technologies, Separation Design Group and ThermalTherapeutics Systems.
"PLSG is committed to identifying and making investments in promising life sciences technologies," said John W. Manzetti, PLSG's President & CEO. Mr. Manzetti continued, "Applied Computational Technologies (AppCompTech), Separation Design Group (SDG) and ThermalTherapeutics Systems (TTS) are three of the compelling companies that PLSG has been working with through our Concept to Commercialization(TM) model. We are excited to add SDG and TTS as new PLSG investment portfolio companies and we are very pleased to continue our support of AppCompTech's product development efforts to commercialize their technology."
The PLSG's $100,000 investment in Separation Design Group will help SDG create a prototype medical oxygen concentrator while also developing smaller, more robust adsorbents; and reducing or eliminating the moisture from the adsorbent package. This product has the potential to revolutionize the entire portable medical oxygen market and significantly improve patient care.
Currently, available portable oxygen systems are too heavy, too noisy, or do not operate long enough without recharging/refilling to facilitate the prescribed therapy. The SDG product will improve the Portable Oxygen Concentrator (POC) technology and minimize the size of the device, vastly improving a patient's overall quality of life and maintain active lifestyles.
The PLSG's $150,000 investment in Applied Computational Technologies will enable the company to propel their product ProACTive(TM) into the marketplace. ProACTive(TM), is AppCompTech's revolutionary radiation dose calculation engine which enables a new generation of highly accurate, extremely fast treatment planning for full adaptive radiotherapy that can eliminate the accuracy/speed trade-off problem that currently exists in the radiation therapy treatment planning process. Until now, both accuracy and speed could not be reached simultaneously during treatment planning. ProACTive's(TM) increased speed and accuracy can create highly precise individualized treatments that will significantly improve patient quality of life and drastically reduce the potential of the radiation destroying the healthy tissue that surrounds the cancerous tumor.
The PLSG's $200,000 investment in ThermalTherapeutics Systems, Inc. will help with the development of a prototype pump for delivering chemotherapy more effectively. The TTS device will deliver both intraperitoneal chemotherapy (IPC) and intraperitoneal hyperthermic chemotherapy (IPHC) to treat metastastic abdominal cancers regardless of primary site, especially ovarian and colon cancer. No device currently exists which has been specifically designed to treat advanced abdominal cancers. The ability to deliver intraperitoneal hyperthermic treatment for disseminated abdominal cancer, therefore, represents a significant advancement in the treatment for a sizable population of cancer patients; substantially improving the quality of life for those undergoing treatment.
The attention that both IPC and IPHC are receiving for the treatment of ovarian, colon, rectal and additional abdominal cancers creates potential for the TTS product to make an important impact on cancer treatment.
About the Pittsburgh Life Sciences Greenhouse (PLSG)
The PLSG invests in and supports the growth of biosciences companies in southwestern Pennsylvania. The PLSG has investment and business growth programs to increase the linkage between research, technology and commercialization; nurture and develop entrepreneurial biosciences enterprises; grow the region's talent pool in the life sciences; and help biosciences firms locate, expand or start-up in the Greater Pittsburgh region. http://www.plsg.com
About Applied Computational Technologies
Applied Computational Technologies, LLC (AppCompTech) is a high-tech software development company formed around its premiere product called ProACTive(TM). ProACTive(TM) is a broad based, patent-pending Particle Transport Simulation technology that is valuable in multiple markets from life sciences to nuclear power. http://www.appcomptech.com
Separation Design Group, LLC
Separation Design Group is an early-stage LLC based in Waynesburg, Pa. SDG has completely re-engineered the small scale oxygen concentrator, developing a proprietary and patent pending technology with components that operate at faster cycle times, resulting in a smaller, lighter, more energy efficient device. SDG's lightweight ambient pressure/temperature oxygen concentrator (LAPTOC) represents a paradigm shift in both form and function from current portable medical oxygen concentrators.
About ThermalTherapeutics Systems, Inc.
ThermalTherapeutics Systems, Inc. (TTS) is developing a specialized pump to enable intraperitoneal chemotherapy (IPC) and intraperitoneal hyperthermic chemotherapy (IPHC) procedures for treating ovarian and other abdominal cancers.
Lynn Banaszak Brusco, Pittsburgh Life Sciences Greenhouse
|SOURCE Pittsburgh Life Sciences Greenhouse|
Copyright©2007 PR Newswire.
All rights reserved